Fmr LLC Increases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Fmr LLC boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 30.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 81,983,231 shares of the company’s stock after purchasing an additional 19,242,468 shares during the quarter. Fmr LLC owned about 0.07% of Teva Pharmaceutical Industries worth $1,806,910,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Quadrant Capital Group LLC raised its holdings in shares of Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after purchasing an additional 949 shares during the period. Russell Investments Group Ltd. raised its holdings in Teva Pharmaceutical Industries by 33.8% in the fourth quarter. Russell Investments Group Ltd. now owns 204,447 shares of the company’s stock valued at $4,506,000 after buying an additional 51,601 shares during the period. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Resona Asset Management Co. Ltd. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $7,211,000. Finally, Pitcairn Co. increased its position in shares of Teva Pharmaceutical Industries by 15.8% in the fourth quarter. Pitcairn Co. now owns 60,887 shares of the company’s stock worth $1,342,000 after acquiring an additional 8,312 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research reports. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $13.83 on Monday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a market cap of $15.68 billion, a price-to-earnings ratio of -9.54, a PEG ratio of 1.44 and a beta of 0.82. The business’s 50 day moving average is $16.52 and its two-hundred day moving average is $18.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.